Phase I/II clinical trials are currently underway to investigate dual‐PI3K/mTOR inhibitors in combination with chemotherapy or targeted therapies in breast cancer, renal cell carcinoma and prostate cancers and have promising results that may be useful for ovarian cancer trials in the future.58 This evidence concerns the gene MTOR and hereditary clear cell renal cell carcinoma.